High levels of NO/cGMP strongly protect against ischemia/reperfusion injury, the protection is largely independent of changes in Ca(2+)(i) modulation, but relates to reduced preischemic performance. Myocyte-specific NO augmentation may aid in studies of the (patho)physiological roles of cardiac-derived NO.
No takes yet. Share an insight, caveat, or question.
Barletta et al. (1988) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: